Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same

• US 20170368190A1
• Filed: 08/09/2017
• Published: 12/28/2017
• Est. Priority Date: 12/19/2005
• Status: Active Grant

• Current Assignee: Pharmain Corporation
• Original Assignee: Pharmain Corporation
• Inventors: Castillo, Gerardo M., Bolotin, Elijah M.
• Granted Patent: US 10,507,248 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/2207 Gastrins; Cholecystokinins [CCK]
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 47/6907 the form being a microemulsion, nanoemulsion or micelle
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/06 of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• CPC Class Codes: A61P 5/18 of the parathyroid hormones
• CPC Class Codes: A61P 5/24 of the sex hormones
• CPC Class Codes: A61P 5/30 Oestrogens
• CPC Class Codes: A61P 5/50 : for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.

Claims

1. A composition, consisting of:

(i) a polymeric carrier;

(ii) a plurality of first hydrophobic groups, wherein each first hydrophobic group of the plurality of first hydrophobic groups is covalently linked to the carrier, is capable of binding a load molecule, and has a molecular weight of less than about 1,000 Daltons independent of the carrier weight;

(iii) a plurality of first protective side chains, wherein each first protective side chain is covalently linked to the carrier and has a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight, and wherein each first protective side chain is polyethylene glycol, polypropylene glycol, a co-polymer of polyethylene glycol and polypropylene glycol, or an alkoxy derivative thereof;

(iv) optionally a plurality of second hydrophobic groups, wherein each second hydrophobic group is covalently linked at a first end to the carrier and is linked at a second end to a second protective side chain having a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight,

wherein each second hydrophobic group is capable of binding a load molecule, has a molecular weight of less than about 1,000 Daltons independent of the carrier weight, and

wherein each second protective chain is polyethylene glycol, polypropylene glycol, a co-polymer of polyethylene glycol and polypropylene glycol, or an alkoxy derivative thereof, and

(v) a load molecule dissociably linked to the hydrophobic groups; and

(vi) a pharmaceutically acceptable excipient,

wherein a weight ratio of total protective side chains to total hydrophobic groups is more than 17;

1 and the composition is soluble in aqueous buffer.

2. The composition of claim 1, wherein each first hydrophobic group comprises an alkyl group of 8-36 carbons and has a molecular weight between 150 to 1000 Daltons independent of the carrier and protective side chain weights.

3. The composition of claim 1, wherein each second hydrophobic group, when present, comprises an alkyl group of 8-36 carbons and has a molecular weight between 150 to 1000 Daltons independent of the carrier and protective side chain weights.

4. The composition of claim 1, wherein the pharmaceutically acceptable excipient is selected from a starch, a sugar, a sugar alcohol, a salt, an amino acid, water, a buffer, a an antioxidant, a preserving agent, a polyol, an antiadhesive, a stabilizer, or a combination thereof.

5. The composition of claim 1, wherein the pharmaceutically acceptable excipient is one or more of an excipient selected from water, a buffer, a preserving agent, and a stabilizer.

6. The composition of claim 1, wherein the pharmaceutically acceptable excipient consists of a buffer, a preserving agent, and a stabilizer.

7. The composition of claim 1, wherein the load molecule is a therapeutic agent selected from the group consisting of glucagon-like-peptide, exenatide, Gastric inhibitory polypeptide (GIP), Epidermal Growth Factor (EGF) receptor ligand, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, Gastrin/Cholecystokinin receptor ligand, interferon, interleukin, tumor necrosis factor, insulin, insulin-like growth factor, growth hormone, nerve growth factor, brain-derived neurotrophic factor, endostatin, angiostatin, thrombospondin, blood clotting factor VII, blood clotting factor VIII, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), thrombopoietin, calcitonin, parathyroid hormone (PTH), erythropoietin, vasopressin, terlipressin, atrial natriuretic factor, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, vasopressin, terlipressin, desmopressin, vasoactive intestinal peptide (VIP), anti-bacterial agents, anti-fungal agents, anti-viral agents, doxorubicin, auristatin, and vitamins.

8. The composition of claim 1, wherein the load molecule is glucagon-like-peptide, Epidermal Growth Factor (EGF) receptor ligand, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, Gastrin/Cholecystokinin receptor ligand, vasopressin, terlipressin, or atrial natriuretic factor.

9. A composition, consisting of

(i) a polymeric carrier;

(ii) a plurality of first hydrophobic groups, wherein each first hydrophobic group of the plurality of first hydrophobic groups is covalently linked to the carrier, is capable of binding a load molecule, and has a molecular weight of less than about 1,000 Daltons independent of the carrier weight;

(iii) a plurality of first protective side chains, wherein each first protective side chain is covalently linked to the carrier and has a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight, and wherein each first protective side chain is polyethylene glycol, polypropylene glycol, a co-polymer of polyethylene glycol and polypropylene glycol, or an alkoxy derivative thereof;

(iv) optionally a plurality of second hydrophobic groups, wherein each second hydrophobic group is covalently linked at a first end to the carrier and is linked at a second end to a second protective side chain having a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight,

wherein each second hydrophobic group is capable of binding a load molecule, has a molecular weight of less than about 1,000 Daltons independent of the carrier weight,

wherein each second protective chain is polyethylene glycol, polypropylene glycol, a co-polymer of polyethylene glycol and polypropylene glycol, or an alkoxy derivative thereof,

(v) a load molecule dissociably linked to the hydrophobic groups;

(vi) an orienting molecule covalently linked to the carrier, wherein the orienting molecule is selected from the group consisting of sulfate, sulfonate, phosphate, phosphonate, bisphosphonate, lysine, and arginine;

(vii) optionally a targeting molecule covalently linked to the first protective side chains; and

(viii) a pharmaceutically acceptable excipient,

wherein a weight ratio of total protective side chains to total hydrophobic groups is more than 17;

1 and the composition is soluble in aqueous buffer.

10. The composition of claim 9, wherein each first hydrophobic group comprises an alkyl group of 8-36 carbons and has a molecular weight between 150 to 1000 Daltons independent of the carrier and protective side chain weights.

11. The composition of claim 9, wherein each second hydrophobic group, when present, comprises an alkyl group of 8-36 carbons and has a molecular weight between 150 to 1000 Daltons independent of the carrier and protective side chain weights.

12. The composition of claim 9, wherein the pharmaceutically acceptable excipient is selected from a starch, a sugar, a sugar alcohol, a salt, an amino acid, water, a buffer, a an antioxidant, a preserving agent, a polyol, an antiadhesive, a stabilizer, or a combination thereof.

13. The composition of claim 9, wherein the pharmaceutically acceptable excipient is one or more of an excipient selected from water, a buffer, a preserving agent, and a stabilizer.

14. The composition of claim 9, wherein the pharmaceutically acceptable excipient consists of a buffer, a preserving agent, and a stabilizer.

15. The composition of claim 9, wherein the load molecule is further dissociably linked to the orienting molecule.

16. The composition of claim 9, wherein the load molecule is a therapeutic agent selected from the group consisting of glucagon-like-peptide, exenatide, Gastric inhibitory polypeptide (GIP), Epidermal Growth Factor (EGF) receptor ligand, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, Gastrin/Cholecystokinin receptor ligand, interferon, interleukin, tumor necrosis factor, insulin, insulin-like growth factor, growth hormone, nerve growth factor, brain-derived neurotrophic factor, endostatin, angiostatin, thrombospondin, blood clotting factor VII, blood clotting factor VIII, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), thrombopoietin, calcitonin, parathyroid hormone (PTH), erythropoietin, vasopressin, terlipressin, atrial natriuretic factor, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, vasopressin, terlipressin, desmopressin, vasoactive intestinal peptide (VIP), anti-bacterial agents, anti-fungal agents, anti-viral agents, doxorubicin, auristatin, and vitamins.

17. The composition of claim 9, wherein the load molecule is glucagon-like-peptide, Epidermal Growth Factor (EGF) receptor ligand, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, Gastrin/Cholecystokinin receptor ligand, vasopressin, terlipressin, or atrial natriuretic factor.

18. The composition of claim 9, wherein the targeting molecule, when present, is selected from the group consisting of monocyte chemotactic protein 1, N-formyl-methionyl-leucyl-phenylalanine, granulocyte-macrophage colony-stimulating factor (GM-CSF), colony stimulating factor-1, granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors, granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies, colony stimulating factor-1 receptors, colony stimulating factor-1 antibodies, platelet factor 4;

TGF-fl growth factor, VEGF growth factor, E-selectin, VCAM-1 adhesive cell-surface glycoprotein, VCAM1fl adhesive cell-surface glycoprotein, 11C-deoxy-D-glucose, C1 component of vascular inflammatory response, C1q component of vascular inflammatory response, C1r component of vascular inflammatory response, C1s component of vascular inflammatory response, C2 component of vascular inflammatory response, C3 component of vascular inflammatory response, C3a component of vascular inflammatory response, C3b component of vascular inflammatory response, C4 component of vascular inflammatory response, C4C2 component of vascular inflammatory response, C4C2C3b component of vascular inflammatory response, C5a component of vascular inflammatory response, C5b component of vascular inflammatory response, C5a component of vascular inflammatory response, interleukin 1, interleukin 10, interleukin 2, interleukin 3, interleukin 6, interleukin 7, interleukin 8, interferon α

, interferon γ

, tumor necrosis factor TNF-α

, polyethylene glycol coated liposomes, cholesterol, esters of cholesterol, LDL lipoprotein, HDL lipoprotein, and oxidized LDL lipoprotein.

19. A composition, consisting of

(i) a polymeric carrier;

(ii) a plurality of first hydrophobic groups, wherein each first hydrophobic group of the plurality of first hydrophobic groups is covalently linked to the carrier, is capable of binding a load molecule, and has a molecular weight of less than about 1,000 Daltons independent of the carrier weight;

(iii) a plurality of first protective side chains, wherein each first protective side chain is covalently linked to the carrier and has a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight, and wherein each first protective side chain is polyethylene glycol, polypropylene glycol, a co-polymer of polyethylene glycol and polypropylene glycol, or an alkoxy derivative thereof;

(iv) optionally a plurality of second hydrophobic groups, wherein each second hydrophobic group is covalently linked at a first end to the carrier, and is linked at a second end to a second protective side chain having a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight,

wherein each second hydrophobic group is capable of binding a load molecule, has a molecular weight of less than about 1,000 Daltons independent of the carrier weight, and wherein each second protective chain is polyethylene glycol, polypropylene glycol, a co-polymer of polyethylene glycol and polypropylene glycol, or an alkoxy derivative thereof,

(v) a load molecule dissociably linked to the hydrophobic groups;

(vi) a targeting molecule covalently linked to the first protective side chains; and

(vii) a pharmaceutically acceptable excipient,

wherein a weight ratio of total protective side chains to total hydrophobic groups is more than 17;

1 and the composition is soluble in aqueous buffer.

20. The composition of claim 19, wherein each first hydrophobic group comprises an alkyl group of 8-36 carbons and has a molecular weight between 150 to 1000 Daltons independent of the carrier and protective side chain weights.

21. The composition of claim 19, wherein each second hydrophobic group, when present, comprises an alkyl group of 8-36 carbons and has a molecular weight between 150 to 1000 Daltons independent of the carrier and protective side chain weights.

22. The composition of claim 19, wherein the pharmaceutically acceptable excipient is selected from a starch, a sugar, a sugar alcohol, a salt, an amino acid, water, a buffer, a an antioxidant, a preserving agent, a polyol, an antiadhesive, a stabilizer, or a combination thereof.

23. The composition of claim 19, wherein the pharmaceutically acceptable excipient is one or more of an excipient selected from water, a buffer, a preserving agent, and a stabilizer.

24. The composition of claim 19, wherein the pharmaceutically acceptable excipient consists of a buffer, a preserving agent, and a stabilizer.

25. The composition of claim 19, wherein the load molecule is a therapeutic agent selected from the group consisting of glucagon-like-peptide, exenatide, Gastric inhibitory polypeptide (GIP), Epidermal Growth Factor (EGF) receptor ligand, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, Gastrin/Cholecystokinin receptor ligand, interferon, interleukin, tumor necrosis factor, insulin, insulin-like growth factor, growth hormone, nerve growth factor, brain-derived neurotrophic factor, endostatin, angiostatin, thrombospondin, blood clotting factor VII, blood clotting factor VIII, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), thrombopoietin, calcitonin, parathyroid hormone (PTH), erythropoietin, vasopressin, terlipressin, atrial natriuretic factor, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, vasopressin, terlipressin, desmopressin, vasoactive intestinal peptide (VIP), anti-bacterial agents, anti-fungal agents, anti-viral agents, doxorubicin, auristatin, and vitamins.

26. The composition of claim 19, wherein the load molecule is glucagon-like-peptide, Epidermal Growth Factor (EGF) receptor ligand, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, Gastrin/Cholecystokinin receptor ligand, vasopressin, terlipressin, or atrial natriuretic factor.

27. The composition of claim 19, wherein the targeting molecule is selected from the group consisting of monocyte chemotactic protein 1, N-formyl-methionyl-leucyl-phenylalanine, granulocyte-macrophage colony-stimulating factor (GM-CSF), colony stimulating factor-1, granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors, granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies, colony stimulating factor-1 receptors, colony stimulating factor-1 antibodies, platelet factor 4;

TGF-fl growth factor, VEGF growth factor, E-selectin, VCAM-1 adhesive cell-surface glycoprotein, VCAM1fl adhesive cell-surface glycoprotein, 11C-deoxy-D-glucose, C1 component of vascular inflammatory response, C1q component of vascular inflammatory response, C1r component of vascular inflammatory response, C1s component of vascular inflammatory response, C2 component of vascular inflammatory response, C3 component of vascular inflammatory response, C3a component of vascular inflammatory response, C3b component of vascular inflammatory response, C4 component of vascular inflammatory response, C4C2 component of vascular inflammatory response, C4C2C3b component of vascular inflammatory response, C5a component of vascular inflammatory response, C5b component of vascular inflammatory response, C5a component of vascular inflammatory response, interleukin 1, interleukin 10, interleukin 2, interleukin 3, interleukin 6, interleukin 7, interleukin 8, interferon α

, interferon γ

, tumor necrosis factor TNF-α

, polyethylene glycol coated liposomes, cholesterol, esters of cholesterol, LDL lipoprotein, HDL lipoprotein, and oxidized LDL lipoprotein.

28. A composition, comprising

(i) a polymeric carrier;

and

(ii) a plurality of first hydrophobic groups, wherein each first hydrophobic group of the plurality of first hydrophobic groups is covalently linked at a first end to the carrier, is capable of binding a load molecule, and has a molecular weight of less than about 1,000 Daltons independent of the carrier weight;

(iii) a plurality of first protective side chains, wherein each first protective side chain is covalently linked to a second end of the first hydrophobic group, and has a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight, and wherein each first protective side chain is polyethylene glycol, polypropylene glycol, a co-polymer of polyethylene glycol and polypropylene glycol, or an alkoxy derivative thereof,

(iv) optionally a plurality of second hydrophobic groups, wherein each second hydrophobic group is covalently linked to the carrier, is capable of binding a load molecule, and has a molecular weight of less than about 1,000 Daltons independent of the carrier weight;

(iii) optionally a plurality of second protective side chains, wherein each second protective side chain is covalently linked to the carrier and has a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight, and wherein each second protective side chain is polyethylene glycol, polypropylene glycol, a co-polymer of polyethylene glycol and polypropylene glycol, or an alkoxy derivative thereof;

(iv) a load molecule dissociably linked to the hydrophobic groups,

(v) optionally an orienting molecule covalently linked to the carrier, wherein the orienting molecule is selected from the group consisting of sulfate, sulfonate, phosphate, phosphonate, bisphosphonate, lysine, and arginine;

(vi) optionally a targeting molecule covalently linked to the first protective side chains; and

(vii) a pharmaceutically acceptable excipient,

wherein the weight ratio of the total protective side chains to the total hydrophobic groups is more than 17;

1 and the composition is soluble in aqueous buffer.

29. The composition of claim 28, wherein each first hydrophobic group comprises an alkyl group of 8-36 carbons and has a molecular weight between 150 to 1000 Daltons independent of the carrier and protective side chain weights.

30. The composition of claim 28, wherein each second hydrophobic group comprises an alkyl group of 8-36 carbons and has a molecular weight between 150 to 1000 Daltons independent of the carrier and protective side chain weights.

31. The composition of claim 28, wherein the pharmaceutically acceptable excipient is selected from a starch, a sugar, a sugar alcohol, a salt, an amino acid, water, a buffer, a an antioxidant, a preserving agent, a polyol, an antiadhesive, a stabilizer, or a combination thereof.

32. The composition of claim 28, wherein the pharmaceutically acceptable excipient is one or more of an excipient selected from water, a buffer, a preserving agent, and a stabilizer.

33. The composition of claim 28, wherein the pharmaceutically acceptable excipient consists of a buffer, a preserving agent, and a stabilizer.

34. The composition of claim 28, wherein the load molecule is a therapeutic agent selected from the group consisting of glucagon-like-peptide, exenatide, Gastric inhibitory polypeptide (GIP), Epidermal Growth Factor (EGF) receptor ligand, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, Gastrin/Cholecystokinin receptor ligand, interferon, interleukin, tumor necrosis factor, insulin, insulin-like growth factor, growth hormone, nerve growth factor, brain-derived neurotrophic factor, endostatin, angiostatin, thrombospondin, blood clotting factor VII, blood clotting factor VIII, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), thrombopoietin, calcitonin, parathyroid hormone (PTH), erythropoietin, vasopressin, terlipressin, atrial natriuretic factor, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, vasopressin, terlipressin, desmopressin, vasoactive intestinal peptide (VIP), anti-bacterial agents, anti-fungal agents, anti-viral agents, doxorubicin, auristatin, and vitamins.

35. The composition of claim 28, wherein the load molecule is glucagon-like-peptide, Epidermal Growth Factor (EGF) receptor ligand, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, Gastrin/Cholecystokinin receptor ligand, vasopressin, terlipressin, or atrial natriuretic factor.

36. The composition of claim 28, wherein the targeting molecule, when present, is selected from the group consisting of monocyte chemotactic protein 1, N-formyl-methionyl-leucyl-phenylalanine, granulocyte-macrophage colony-stimulating factor (GM-CSF), colony stimulating factor-1, granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors, granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies, colony stimulating factor-1 receptors, colony stimulating factor-1 antibodies, platelet factor 4;

TGF-fl growth factor, VEGF growth factor, E-selectin, VCAM-1 adhesive cell-surface glycoprotein, VCAM1fl adhesive cell-surface glycoprotein, 11C-deoxy-D-glucose, C1 component of vascular inflammatory response, C1q component of vascular inflammatory response, C1r component of vascular inflammatory response, C1s component of vascular inflammatory response, C2 component of vascular inflammatory response, C3 component of vascular inflammatory response, C3a component of vascular inflammatory response, C3b component of vascular inflammatory response, C4 component of vascular inflammatory response, C4C2 component of vascular inflammatory response, C4C2C3b component of vascular inflammatory response, C5a component of vascular inflammatory response, C5b component of vascular inflammatory response, C5a component of vascular inflammatory response, interleukin 1, interleukin 10, interleukin 2, interleukin 3, interleukin 6, interleukin 7, interleukin 8, interferon α

, interferon γ

, tumor necrosis factor TNF-α

, polyethylene glycol coated liposomes, cholesterol, esters of cholesterol, LDL lipoprotein, HDL lipoprotein, and oxidized LDL lipoprotein.